Scarica l'app Stockscreener
77.91
3.18%
-2.56
Kiniksa Pharmaceuticals International Plc Borsa (KNSA) Ultime notizie
Megna Michael R Reduces Kiniksa Holdings to 29,062 Shares Following Sale and Other Transactions - Kalkine Media
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - GuruFocus
Kiniksa Pharmaceuticals COO Moat Ross Executes Significant Equity Transactions on September 1, 2026 - Kalkine Media
Kiniksa sets a live healthcare talk for Sept. 9 - Stock Titan
Kiniksa CFO Mark Ragosa Reports RSU Vestings, Tax Withholding Share Sale, and New Equity Grants - Kalkine Media
Kiniksa Pharmaceuticals CEO Sanj K Patel Reports RSU Vesting, Share Sale, and New Equity Grants - Kalkine Media
Kiniksa (NASDAQ: KNSA) grants 14,600 options and 3,650 RSUs to Michael Megna - Stock Titan
Kiniksa (NASDAQ: KNSA) grants CMO options and RSUs - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares - MarketBeat
Kiniksa Pharmaceuticals (KNSA) gives CEO new 10-year stock option grant - Stock Titan
Kiniksa (KNSA) CEO gets new equity grants vesting over four years - Stock Titan
Kiniksa Pharmaceuticals (KNSA) awards CFO new equity - Stock Titan
Officer at Kiniksa (NASDAQ: KNSA) plans $369K stock sale - Stock Titan
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa stock holds firm after a $243.6 million quarter - AD HOC NEWS
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kiniksa (KNSA) Earnings Reading: The EPS Result Is Below Expectation in the Current Update; Share Move: The Market Price Advances 1.03% at the CloseProfitability Analysis - vinanet.vn
Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund - Kalkine Media
Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund - Stock Titan
Kiniksa (KNSA) Earnings Report: EPS Comes in Below Forecast in the Reported Period; Trading Move: Shares Move 2.88% Lower on the DayEarnings Revision Downgrade - vinanet.vn
Kiniksa Pharmaceuticals International PLC - TradingKey
Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story - ChartMill
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 3. - GuruFocus
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - sharewise.com
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals (KNSA) Holds Near $76.53 as Bulls Eye $80.36 ResistanceBPI Bull Correction - vinanet.vn
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
ผลประกอบการ ที่แข็งแกร่งของ Kiniksa Pharmaceuticals International (NASDAQ:KNSA) เป็นผลประกอบการที่มีคุณภาพดี - moomoo.com
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Slides 5.2% to $74.14 as Key Support Level LoomsSmart Beta Flow - vinanet.vn
Kiniksa Pharmaceuticals (KNSA) Pulls Back After Recent Rally: Key Levels in FocusThematic ETF Flow - vinanet.vn
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98 - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $107.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00 - MarketBeat
Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $79.62, Implies 25% Upside - TradingView
Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA) - simplywall.st
KNSA Looks 59.8% Overvalued on GF Value™ After Q2 Earnings Surge - GuruFocus
KNSA Looks 58.0% Overvalued on GF Value™ as Shares Surge 22.7% - GuruFocus
KNSA Looks 59.0% Overvalued on GF Value™ as Shares Surge Amid Mi - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $99 From $72, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighWhat's Next? - MarketBeat
KNSA: Record ARCALYST sales and strong pipeline progress drove raised 2026 guidance and cash growth - TradingView
Kiniksa Pharmaceuticals International, plc Provides Earnings Guidance for Year 2026 - marketscreener.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates - Yahoo Finance
KNSA: Q2 2026 delivered 55% YoY ARCALYST sales growth and raised 2026 revenue guidance to $980–$995M - TradingView
Is Kiniksa Pharmaceuticals (KNSA) Overvalued After Q2 Earnings B - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Reports Q2 2026 Numbers - AlphaStreet
Kiniksa Pharmaceuticals stock rises 2% on raised guidance, revenue beat By Investing.com - Investing.com Nigeria
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):